Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan

Published: Thursday, January 30, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.

Horizon Discovery™ announce that it has entered into a large-scale licensing agreement with a Japanese medical university. The agreement covers a limited use label license for academic use of 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines, and demonstrates the global recognition of the company’s in vitro disease models.

Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly other diseases. Horizon creates these cell lines using its precision genome-editing GENESIS™ platform, consisting of rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations. These models help researchers understand how complex genetic diseases manifest themselves in patients, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development including target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.

Kam Dhaliwal, VP Sales, Horizon Discovery, commented: “This is a very significant deal for Horizon Discovery, covering a large number of cell lines and representing a large investment by the university. We are delighted that our distribution partnership in Japan with Summit Pharmaceuticals International (SPI) is proving so productive.  Summit has proven to be extremely effective in opening the Japanese market for Horizon and we anticipate further adoption of our products and services in Japan in the future.”

The director of the Translational Research Centre at the university commented: “Horizon’s X-MAN cell lines offer a unique and valuable resource for the study of specific, disease-related mutations. We are look forward to applying the X-MAN technology in our research projects.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Announces Strategic Partnership with Promega
Partnership to combine Horizon’s genome editing technology with Promega’s reporter technologies to enable personalized drug development.
Tuesday, November 08, 2011
University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
The collaboration will identify and validate novel cancer targets and biomarkers for personalized cancer therapy and diagnostics.
Monday, October 19, 2009
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Peptides vs. Superbugs
Scientists successfully develop a shuttle system made of liquid-crystalline nanomaterials that protect peptites.
Immune Approach Targets Humans Instead of Bacteria
Scientists show for the first time how bacterial superantigen toxins work, and how short peptides can block them and save lives.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos